AML

Orphan designation: cusatuzumab Treatment of acute myeloid leukaemia, 22/04/2020 Positive

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Clinical research, Health, B cell, Growth, Cell, Bone marrow, Infection, AML, Disease, Patient, Committee, Knowledge, Regulation, CD70, Cancer, EMA, IRIS, Business park, Acute myeloid leukemia, European, COMP, European Commission, Blood, Azacitidine, Safety, Haematopoietic system, Marketing, Acute leukemia, Medicine, Pharmaceutical industry

Orphan designation: cusatuzumab Treatment of acute myeloid leukaemia, 22/04/2020 Positive

Key Points: 


Orphan designation: cusatuzumab Treatment of acute myeloid leukaemia, 22/04/2020 Positive

Feedback on the input provided by the European Parliament as part of its resolution on the ECB’s Annual Report 2022

Retrieved on: 
Thursday, April 18, 2024
Crypto, European banking union, Governance, Exercise, TARGET, Ciccarelli, Single, Climate, OJ, Ethics, Carbon, ECRB, Parliament, Council, European Systemic Risk Board, European Commission, Paris Agreement, Television, Annual, Letter, Speech, Employment, Social, ESRB, Euro, Prejudice, FSB, AML, ECB, Blog, Risk, ESCB, Committee, NGFS, Policy, Woman, Suggestion, Radio, GDP, Privacy, Weather, Person, Climate change, Communication, Digital, Intelligence, Economic and monetary union, SSM, Bias, Knowledge, Mentorship, EMU, Commission, Economy, Publication, Annual report, Financial Action Task Force, Orientation, Nickel, NPL, European Central Bank, Uncertainty, Financial Stability Board, Conference, NCBS, Treaty, Growth, Financial system, Central bank, European Parliament, Network, Natural Resources, COVID-19, Terrorism, Bank, Female, IMF, Multi-function printer, Recreation, Memorandum, Data, AMLA, Security printing

Beyond managing related risks, the financial sector can also contribute to the transition toward a net-zero economy.

Key Points: 
  • Beyond managing related risks, the financial sector can also contribute to the transition toward a net-zero economy.
  • Our work aims to enhance data transparency in climate change analysis, while informing monetary policy, financial stability and banking supervision.
  • The indicators we have developed focus on the euro area financial sector and are built from harmonised granular datasets.

Cepheus Pay Acquires Key Licence from AIFC, Marking a Major Step in Its Global Expansion Strategy

Retrieved on: 
Thursday, April 4, 2024
Growth, Environment, AML, Trust, AFSA, Acquisition, Cepheus, Nursultan Nazarbayev International Airport, Cryptocurrency

Positioned strategically in Central Asia, it serves as a critical bridge connecting the Eastern and Western markets, offering Cepheus Pay strategic advantages for expansion.

Key Points: 
  • Positioned strategically in Central Asia, it serves as a critical bridge connecting the Eastern and Western markets, offering Cepheus Pay strategic advantages for expansion.
  • For Cepheus Pay, maintaining these standards is vital to earning trust and establishing a solid reputation within the financial sector.
  • Emphasizing the importance of this achievement, Cepheus Pay Group Chairman Izmir Ismayilov stated, "Obtaining the Providing Money Services license from the AIFC marks a crucial milestone in our expansion strategy.
  • Beyond regulatory compliance, the AIFC offers Cepheus Pay access to a rich network of financial experts, research resources, and investment opportunities.

The Hunt for the Best in Fintech - Leadership, Innovation, AI Technology Shaping Future Growth

Retrieved on: 
Wednesday, March 20, 2024
Machine learning, Consumer, Growth, Klarna, IPhone, AML, ACH, Blockchain, Zettle, Muumuu, CNBC, Statista, Revolut, Research, Stripe, News, Ant Group, CME, Investment, Cloud computing, Fraud, Venmo, Chicago Mercantile Exchange, BSA, Patent, Iconic, Artificial intelligence, Cryptocurrency

Report Ocean says, "The global Fintech market is on an unparalleled growth trajectory, projected to soar at an impressive CAGR of 25.0% from 2022 to 2028.

Key Points: 
  • Report Ocean says, "The global Fintech market is on an unparalleled growth trajectory, projected to soar at an impressive CAGR of 25.0% from 2022 to 2028.
  • "Escalating investments in technology-driven solutions, including Artificial Intelligence (AI), Machine Learning (ML), cloud computing, and blockchain, are propelling the Fintech sector forward."
  • With strong growth on the horizon for Fintech stocks, the Industry is recognizing excellence and innovation in payments and financial technology to showcase the leaders.
  • For investors, industry recognition is another tool for due diligence, but using the company's technology is the best first hand test for defining the winners of the future.

Exnode Announces Exnode Pay: Secure Crypto Processing Goes Global

Retrieved on: 
Tuesday, March 19, 2024
Risk, Python, PHP, AML, Cryptocurrency

Tbilisi, Georgia--(Newsfile Corp. - March 19, 2024) - Exnode, a leading provider of secure crypto processing and merchant services, announces Exnode Pay for the international market.

Key Points: 
  • Tbilisi, Georgia--(Newsfile Corp. - March 19, 2024) - Exnode, a leading provider of secure crypto processing and merchant services, announces Exnode Pay for the international market.
  • By expanding its operations into the global market, Exnode Pay offers a reliable and secure payment processing alternative, instilling confidence in businesses of all sizes.
  • Exnode Pay delivers a robust suite of features for international businesses, including:
    Unparalleled Reliability: 99.9% uptime ensures seamless transaction processing.
  • After six years on the market, Exnode has established itself as a trusted brand in the crypto processing industry.

Animoca Brands and Blockpass forge strategic partnership for a secure and regulatory compliant Web3

Retrieved on: 
Friday, March 15, 2024
Blockpass, Grand Prix motorcycle racing, Partnership, Trust, Animoca Brands, Blockchain, KYC, Walking Dead, Environment, KYC/AML, Investment, AI, AML, Cryptocurrency

This collaboration will leverage Blockpass' industry-leading KYC/AML SaaS to provide Animoca Brands and select portfolio companies with seamless and cost-effective solutions for user verification.

Key Points: 
  • This collaboration will leverage Blockpass' industry-leading KYC/AML SaaS to provide Animoca Brands and select portfolio companies with seamless and cost-effective solutions for user verification.
  • This strategic partnership will enable Blockpass to tap into the potential of Animoca Brands' ecosystem while enhancing our user verification process."
  • "Animoca Brands has been an important customer of Blockpass since 2021 and we're excited to further our relationship," said Adam Vaziri, CEO of Blockpass.
  • By prioritizing user safety, regulatory compliance, and user experience, Blockpass and Animoca Brands are paving the way for a more secure and inclusive future for the decentralized world.

Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

Retrieved on: 
Tuesday, April 9, 2024
Toxicity, Flow cytometry, Labs, Bone marrow, AML, Patient, Cytarabine, Acute myeloid leukemia, PLK1, AACR, BSA, De novo, Poster, Pharmaceutical industry

“We are very pleased to share more data regarding our clinical program and proprietary platform with the oncology community at AACR 2024.

Key Points: 
  • “We are very pleased to share more data regarding our clinical program and proprietary platform with the oncology community at AACR 2024.
  • Our clinical program will incorporate the co-development of a companion diagnostic test,” said Thomas Bock, M.D., Chief Executive Officer of Notable.
  • Notable Labs provided an updated plan for the design of an open label Phase 2 study, including a dose optimization plan aimed at reducing toxicity while maintaining efficacy and an overview of study objectives and endpoints.
  • These preliminary metrics predict that 32-33% of de novo patients and 25% of R/R AML patients would be predicted to be responders if they were treated with volasertib.

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Retrieved on: 
Tuesday, April 9, 2024
Acute leukemia, Canadian Aviation Regulations, Cell, CD33, AML, Patient, Tissue, CML, Acute myeloid leukemia, Leukemia, Death, AACR, Neoplasm, Cancer, Safety, CD123, Antigen, Vaccine

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced new preclinical data from its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell (nsCAR) platform, known as INB-300, that demonstrated improved selectivity to target leukemia cells while preserving healthy ones. The data support the potential for nsCAR to have a wider therapeutic window and to be used to prevent on-target off-tumor killing of healthy tissue that may express the CAR-T target. The data was presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024 on April 9, 2024.

Key Points: 
  • The data was presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024 on April 9, 2024.
  • IN8bio's nsCAR platform is based on the natural ability of gamma-delta T cells to distinguish between healthy and malignant tissue.
  • Approved CAR-T therapies have shown remarkable efficacy against B cell malignancies, offering hope to patients with limited treatment options.
  • “These results can potentially improve INB-300, as we advance towards IND enabling studies of our next-generation gamma-delta T cell therapies to treat cancers.”

Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
KAT2B, Gene, Algorithm, Growth, AML, Carcinoma, DRIVE, Biomarker, Acute myeloid leukemia, Cancer, AI, Developmental biology, NEPC, Senior, Translation, AACR, Doctor of Philosophy, Neoplasm, Therapy, Machine learning, Annual general meeting, Vaccine

NEWTON, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The Company highlighted the distinct ability of its AURIGIN™ platform to identify both cell state plasticity, the proliferative state in which cancer cells grow, and the causative gene targets. In a second poster, Auron shared preclinical data from its program targeting KAT2A/B, an AURIGIN-identified histone acetyltransferase driving small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and acute myeloid leukemia (AML). These data led to the nomination of AUTX-703, an orally available and selective KAT2A/B degrader development candidate, for which Auron expects to file an IND in 2024.

Key Points: 
  • The Company highlighted the distinct ability of its AURIGIN™ platform to identify both cell state plasticity, the proliferative state in which cancer cells grow, and the causative gene targets.
  • In a second poster, Auron shared preclinical data from its program targeting KAT2A/B, an AURIGIN-identified histone acetyltransferase driving small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and acute myeloid leukemia (AML).
  • These data led to the nomination of AUTX-703, an orally available and selective KAT2A/B degrader development candidate, for which Auron expects to file an IND in 2024.
  • “The understanding that cellular plasticity contributes to aggressive and treatment-resistant tumor growth underscores the need for innovative, targeted approaches.

Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform

Retrieved on: 
Monday, April 8, 2024
Find, White blood cell, AML, Patient, Acute myeloid leukemia, Cancer, AACR, Cryopreservation, Therapy, Pharmaceutical industry

“We are very pleased to share the result of our innovative sample handling study with the cancer community at AACR 2024.

Key Points: 
  • “We are very pleased to share the result of our innovative sample handling study with the cancer community at AACR 2024.
  • The ability to derive a high-quality assessment of the response to treatment based on the results of cryopreserved samples is an important innovation.
  • It has been previously thought that frozen samples could not be effectively thawed and used for cell viability assays.
  • While Notable will continue to evaluate and validate these sample handling methodologies, these data open the door to the use of cryopreserved samples from retrospective cohorts.